Schedule 13G ownership disclosure

Inhibikase Therapeutics Inc

Common Stock, $0.001 par value · CUSIP: 45719W205

Event date: 2024-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Nantahala Capital Management, LLC

    Shares: 5,298,624.00 · Class: 7.54%

  • Wilmot B. Harkey

    Shares: 5,298,624.00 · Class: 7.54%

  • Daniel Mack

    Shares: 5,298,624.00 · Class: 7.54%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-25-014198
Form type
SCHEDULE 13G
Filer
Inhibikase Therapeutics, Inc.
CIK
CIK 1750149
Filed
Feb 14, 2025
Reporting period
Dec 31, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub